ReviewOncology reports2025
Potential therapeutic target in oncology: Protein palmitoylation (Review).
Review in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Post-Translational Modifications in Pancreatic Cancer: Mechanisms to Clinical Applications.Journal of gastroenterology and hepatology · 2026Review
- A palmitoylation signature for prognosis immune infiltration and drug sensitivity in esophageal carcinoma.iScience · 2026Article
- SMAD4 Palmitoylation Drives a Metabolic-Transcriptional Circuit to Promote Tumorigenesis and Confers Radiosensitivity in Pancreatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- ZDHHC-Mediated Protein S-Palmitoylation in Cancer: Epigenetic Interfaces, Structural Logic and Therapeutic Targeting.International journal of medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post‑translational modifications (PTMs) of proteins, by altering the structural conformation of precursor polypeptides, play an indispensable role in augmenting the diversity and stability of the proteome. PTMs exert profound influence on various hallmarks of tumor biology, including cellular proliferation, apoptosis, angiogenesis and metastatic dissemination. Accordingly, advancing our understanding of PTMs holds substantial promise for broadening the therapeutic landscape of oncology. Among these modifications, palmitoylation, a reversible lipid‑based PTM, critically modulates protein stability, membrane localization, protein‑protein interactions and signal transduction cascades. Dysregulation of palmitoylation has been increasingly implicated in tumorigenesis, suggesting its aberrant forms as putative targets for therapeutic intervention. The present review delineates the biochemical mechanisms underlying protein palmitoylation and synthesizes current insights into its multifaceted roles in tumor progression, immune modulation and metabolic regulation, thereby offering novel perspectives for the development of targeted cancer therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.